Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › BGM0504

BGM0504

GIP/GLP-1 · s.c. · BrightGene

Data cut 12 November 2026 · page built 16 November 2026 · 6 trial arms · 2 trials with results · 5 registered trials · see on the pipeline board

Summary

Also known as
BrightGene
Mechanism
GIP/GLP-1
Route
s.c.
Company
BrightGene
Highest development stage
filed
Status (as of data cut)
Phase 3 positive in China (52 weeks, up to −19.2 %); NDA accepted (June 2026) verify
Next milestone
China approval

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity3 positive phase 3Positive phase 3 in China; NDA accepted June 2026BrightGene NDA announcement (Jun 2026); BGM0504 phase 3 (EASD 2026)
T2D2 phase 3 ongoingPhase 3 registered on ClinicalTrials.gov
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH0 no data
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
BGM0504 phase 2 (China, obesity)BGM0504 5 mgobesity china24———−10.7 % vs +0.1 %
estimand not specified
———————verified
BGM0504 phase 2 (China, obesity)BGM0504 10 mgobesity china24———−16.1 % vs +0.1 %
estimand not specified
———————verified
BGM0504 phase 2 (China, obesity)BGM0504 15 mgobesity china24———−18.3 % vs +0.1 %
estimand not specified
———————verified
BGM0504 phase 3 (obesity)BGM0504 15 mgobesity china52——−19.2 % vs −3.1 %
Δ −16.1 pp
—0.7—————verified
BGM0504 phase 3 (obesity)BGM0504 10 mgobesity china52——−17.3 % vs −3.1 %
Δ −14.2 pp
—1.2—————verified
BGM0504 phase 3 (obesity)BGM0504 5 mgobesity china52——−14.3 % vs −3.1 %
Δ −11.2 pp
—1.7—————verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (9)
  • BGM0504 15 mg · weight_tp · Results
    15 mg: −19.19% (95% CI: −20.63 to −17.76), corresponding to −18.26 kg (95% CI: −19.66 to −16.86)
  • BGM0504 15 mg · ae_dc · HKEX filing
    BGM0504 注射液治疗 52 周各剂量组因不良事件导致的终止治疗比例分别为 1.7%、1.2%和 0.7%
  • BGM0504 10 mg · weight_tp · Results
    10 mg: −17.27% (95% CI: −18.67 to −15.88), corresponding to −16.47 kg (95% CI: −17.85 to −15.09)
  • BGM0504 10 mg · ae_dc · HKEX filing
    BGM0504 注射液治疗 52 周各剂量组因不良事件导致的终止治疗比例分别为 1.7%、1.2%和 0.7%
  • BGM0504 5 mg · weight_tp · Results
    5 mg: −14.31% (95% CI: −15.69 to −12.93), corresponding to −13.48 kg (95% CI: −14.83 to −12.13)
  • BGM0504 5 mg · ae_dc · HKEX filing
    BGM0504 注射液治疗 52 周各剂量组因不良事件导致的终止治疗比例分别为 1.7%、1.2%和 0.7%
  • BGM0504 5 mg · weight_unsp · Abstract
    Mean percentage changes in body weight from baseline to week 24 were -10.68%
  • BGM0504 10 mg · weight_unsp · Abstract
    Mean percentage changes in body weight from baseline to week 24 were -10.68%
  • BGM0504 15 mg · weight_unsp · Abstract
    Mean percentage changes in body weight from baseline to week 24 were -10.68%

Registered trials (5)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
NCT07743983 · China
A Study of BGM0504 in Early T2DM With Obesity
T2DPhase 3recruiting2026-09 → 2028-09372recruitingNCT07743983
NCT07064486
A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
T2DPhase 3active not recruiting2025-07 → 2027-04152active not recruitingNCT07064486
NCT06716203
A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
T2DPhase 3completed2025-01 → 2026-08227Completed; results not in the atlas yetNCT06716203
NCT06716216
A Study of BGM0504 in Participants With Type 2 Diabetes
T2DPhase 3completed2025-01 → 2026-08553Completed; results not in the atlas yetNCT06716216
NCT06704581 · China
A Study of BGM0504 Injection in Participants With Obesity or Overweight
ObesityPhase 3completed2024-10 → 2026-03652Completed; results not in the atlas yetNCT06704581

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: BGM0504. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/bgm0504/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.